N/A N=71 Multi-center Evaluation of the NEMO Gauge to Aid in Correct Positioning of the Endotracheal Tube
Respiratory Failure
Primary: Number of Correct Endotracheal Tube Position — 64 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 A Group-Based Walking Study Using WeChat to Enhance Physical Activity Among Older Adults
Inactivity · Sedentary Behavior
Primary: Number of Steps Walked — 3992; 4125; 4171; 5872 steps — p=0.02
Phase 3 N=1,270 Treatment of Pain Associated With Fibromyalgia
Pain Associated With Fibromyalgia
Primary: Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) in Participants Receiving DS-5565, Pregabalin, or Placebo — -1.86; -2.47; -2.24; -2.09 units on a…
N/A N=56 Mindfulness Based Stress Reduction for High Blood Pressure
Hypertension
Primary: SBP — 130.2; 128.8 mm Hg
N/A N=1,356 STRIPES Study: Study To Reduce Infection Post cEsarean Section
Chlorhexidine Gluconate Cloths · Infection; Cesarean Section · Infectious Morbidity
Primary: Number of Participants With Incisional SSI — 17; 24 Participants
Phase 3 N=330 Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Muscle Wasting · Non-Small Cell Lung Cancer
Primary: Physical Function — 19.5; 24.8 percentage of subjects
Phase 3 N=88 Colloids in Pediatric Cardiac Surgery: Comparison Between a Balanced and a Non-balanced Colloid
Cardiac Surgery · Cardiopulmonary Bypass
Primary: Calculated Blood Loss at 3rd Post Operative Day (POD) — 19.9; 15.9 ml/kg
Phase 2 N=8 Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Urothelial Carcinoma · Bladder Cancer · Urinary Bladder Neoplasms
Primary: Percentage of Participants Who Enrolled and Underwent a Biopsy Who Went on to Receive Treatment Within 21 Days — 63 percentage of participants
Phase 1 N=16 Evaluate Severe Hepatic Impairment on Dacomitinib PK
Severe Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Dacomitinib — 9.673; 7.389 nanogram per milliliter
Phase 3 N=472 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
Leukemia, Myeloid, Acute
Primary: Kaplan-Meier (K-M) Estimate for Overall Survival (OS) — 24.7; 14.8 Months — p=0.0009
N/A N=158 Longitudinal Phenotyping of Bariatric Surgery Patients
Obesity · Diabetes Mellitus, Type 2
Primary: Number of Participants With Complete Diabetes Remission at 3 Months — 8; 5 Participants
Phase 2 N=134 Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Atrial Fibrillation Burden (AFB) at Baseline — 12.7; 10.8; 11.6; 11.7 Percentage of total recording time
Phase 2 N=108 A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
Prostate Cancer
Primary: Part 2: Percentage of Participants With Objective Tumor Response (Response Rate) — 15.2; 15.0 percentage of participants — p=1.0000
Phase 2 N=23 Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Treatment-Emergent Adverse Events (AEs) — 4; 11 Participants
Phase 2 N=64 A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
Pterygium
Primary: Change From Baseline in Overall Conjunctival Hyperemia Score — -0.056; -0.330; -0.352 score on a scale — p=0.218